Capricor reports third quarter 2026 financial results
It posts a $42.7 million net loss and $198.5 million in cash, while its Deramiocel BLA stays under FDA review with a November 22, 2026 PDUFA date.
See the latest news and media coverage for Capricor. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing cell and exosome-based therapeutics
capricor.comLast updated
In short: Capricor’s FDA review of Deramiocel was extended to November while 24-month HOPE-3 data showed slower upper-limb decline.
It posts a $42.7 million net loss and $198.5 million in cash, while its Deramiocel BLA stays under FDA review with a November 22, 2026 PDUFA date.
Deramiocel slowed upper limb decline by 76% in DMD patients during the open-label extension study. Data were submitted as part of the Biologics License Application ahead of the November 22 PDUFA date.
The company submitted additional Phase 3 data supporting a refined indication for upper limb function, causing the FDA to classify the filing as a major amendment requiring three extra months for review.
Cash at $238M, net loss widened to $40.7M, FDA advisory committee voted against, but HOPE-3 published in The Lancet.
The amendment includes two-year Phase 3 HOPE-3 extension data and an integrated efficacy summary across HOPE-2 and HOPE-3.
SAN DIEGO (AP) — SAN DIEGO (AP) — Capricor Therapeutics Inc. (CAPR) on Tuesday reported a loss of $42.7 million in its third quarter. On...
What is deramiocel being developed for? Deramiocel is an investigational allogeneic cardiosphere-derived cell therapy being developed by Capricor Therapeutics to treat Duchenne muscular dystrophy, with...
Capricor Therapeutics said on Monday the U.S. Food and Drug Administration had extended the review ...
Track Capricor and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Capricor and other trending companies.